Cancer clinical trials in the region Île-de-France
750 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07544654
#2025-523869-22-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
4 recruiting sites
Boehringer Ingelheim
Phase 3
Skin cancer
#NCT06743126
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Immatics US, Inc.
Phase 3
Lung cancer
#NCT06899126
#2024-515658-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Antibody Drug Conjugates (ADC)
16 recruiting sites
Daiichi Sankyo
Phase 3
Stomach and esophageal cancer
#NCT06731478
#2024-513122-27-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
15 recruiting sites
Daiichi Sankyo
Phase 3
Skin cancer
#NCT06246149
#2023-510333-28-00
Required histologic types
Melanoma
Required histologic sub types
Choroidal melanoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Systemic Treatment-Naive
2 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Breast cancer
#NCT07106632
#2024-519655-28-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
25 recruiting sites
UNICANCER
Phase 3
Lung cancer
#NCT07361510
#2025-523586-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Bristol-Myers Squibb
Phase 3
Skin cancer
#NCT06112314
Required histologic types
Melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Immunocore Ltée
Phase 3
Skin cancer
#NCT05549297
Required histologic types
Melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Immunocore Ltée
Phase 3
Skin cancer
#NCT05727904
#2022-503140-41-00
Required histologic types
Melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Iovance Biotherapeutics